Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability